曲妥珠单抗
医学
转移性乳腺癌
肿瘤科
内科学
乳腺癌
化疗
佐剂
靶向治疗
癌症
作者
Lucia Del Mastro,Matteo Lambertini,Claudia Bighin,Alessia Levaggi,A. D'Alonzo,S. Giraudi,Paolo Pronzato
摘要
Trastuzumab is a humanized monoclonal antibody against the extracellular domain of hEGF receptor-2 (HER2). Trastuzumab in combination with chemotherapy has proven efficacy in treating both early and metastatic HER2-positive breast cancer. In the metastatic setting, the addition of trastuzumab to chemotherapy is associated with a statistically significant longer time to disease progression, higher rate of objective response and improvement in overall survival. Trastuzumab efficacy is not influenced by hormone receptor status, but differences in median overall survival exist between HER2-positive and HER2-negative states. Reassessment of the benefit of re-exposing patients with metastatic breast cancer to trastuzumab following relapse in the adjuvant setting is necessary. Ongoing research into new HER2-targeted therapies and trials involving combination anti-HER2 drug therapy without chemotherapy show promise. This review is focused on the available results obtained with the use of trastuzumab in the subset of HER2-positive breast cancer patients with metastatic disease.
科研通智能强力驱动
Strongly Powered by AbleSci AI